Cargando…
Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB
Acoustic signal analysis has been employed in various medical devices. However, studies involving cough sound analysis to screen the potential pulmonary tuberculosis (PTB) suspects are very few. The main objective of this cross-sectional validation study was to develop and validate the Swaasa AI pla...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034902/ https://www.ncbi.nlm.nih.gov/pubmed/36959347 http://dx.doi.org/10.1038/s41598-023-31772-9 |
_version_ | 1784911308354748416 |
---|---|
author | Yellapu, Gayatri Devi Rudraraju, Gowrisree Sripada, Narayana Rao Mamidgi, Baswaraj Jalukuru, Charan Firmal, Priyanka Yechuri, Venkat Varanasi, Sowmya Peddireddi, Venkata Sudhakar Bhimarasetty, Devi Madhavi Kanisetti, Sidharth Joshi, Niranjan Mohapatra, Prasant Pamarthi, Kiran |
author_facet | Yellapu, Gayatri Devi Rudraraju, Gowrisree Sripada, Narayana Rao Mamidgi, Baswaraj Jalukuru, Charan Firmal, Priyanka Yechuri, Venkat Varanasi, Sowmya Peddireddi, Venkata Sudhakar Bhimarasetty, Devi Madhavi Kanisetti, Sidharth Joshi, Niranjan Mohapatra, Prasant Pamarthi, Kiran |
author_sort | Yellapu, Gayatri Devi |
collection | PubMed |
description | Acoustic signal analysis has been employed in various medical devices. However, studies involving cough sound analysis to screen the potential pulmonary tuberculosis (PTB) suspects are very few. The main objective of this cross-sectional validation study was to develop and validate the Swaasa AI platform to screen and prioritize at risk patients for PTB based on the signature cough sound as well as symptomatic information provided by the subjects. The voluntary cough sound data was collected at Andhra Medical College-India. An Algorithm based on multimodal convolutional neural network architecture and feedforward artificial neural network (tabular features) was built and validated on a total of 567 subjects, comprising 278 positive and 289 negative PTB cases. The output from these two models was combined to detect the likely presence (positive cases) of PTB. In the clinical validation phase, the AI-model was found to be 86.82% accurate in detecting the likely presence of PTB with 90.36% sensitivity and 84.67% specificity. The pilot testing of model was conducted at a peripheral health care centre, RHC Simhachalam-India on 65 presumptive PTB cases. Out of which, 15 subjects truly turned out to be PTB positive with a positive predictive value of 75%. The validation results obtained from the model are quite encouraging. This platform has the potential to fulfil the unmet need of a cost-effective PTB screening method. It works remotely, presents instantaneous results, and does not require a highly trained operator. Therefore, it could be implemented in various inaccessible, resource-poor parts of the world. |
format | Online Article Text |
id | pubmed-10034902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100349022023-03-23 Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB Yellapu, Gayatri Devi Rudraraju, Gowrisree Sripada, Narayana Rao Mamidgi, Baswaraj Jalukuru, Charan Firmal, Priyanka Yechuri, Venkat Varanasi, Sowmya Peddireddi, Venkata Sudhakar Bhimarasetty, Devi Madhavi Kanisetti, Sidharth Joshi, Niranjan Mohapatra, Prasant Pamarthi, Kiran Sci Rep Article Acoustic signal analysis has been employed in various medical devices. However, studies involving cough sound analysis to screen the potential pulmonary tuberculosis (PTB) suspects are very few. The main objective of this cross-sectional validation study was to develop and validate the Swaasa AI platform to screen and prioritize at risk patients for PTB based on the signature cough sound as well as symptomatic information provided by the subjects. The voluntary cough sound data was collected at Andhra Medical College-India. An Algorithm based on multimodal convolutional neural network architecture and feedforward artificial neural network (tabular features) was built and validated on a total of 567 subjects, comprising 278 positive and 289 negative PTB cases. The output from these two models was combined to detect the likely presence (positive cases) of PTB. In the clinical validation phase, the AI-model was found to be 86.82% accurate in detecting the likely presence of PTB with 90.36% sensitivity and 84.67% specificity. The pilot testing of model was conducted at a peripheral health care centre, RHC Simhachalam-India on 65 presumptive PTB cases. Out of which, 15 subjects truly turned out to be PTB positive with a positive predictive value of 75%. The validation results obtained from the model are quite encouraging. This platform has the potential to fulfil the unmet need of a cost-effective PTB screening method. It works remotely, presents instantaneous results, and does not require a highly trained operator. Therefore, it could be implemented in various inaccessible, resource-poor parts of the world. Nature Publishing Group UK 2023-03-23 /pmc/articles/PMC10034902/ /pubmed/36959347 http://dx.doi.org/10.1038/s41598-023-31772-9 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Yellapu, Gayatri Devi Rudraraju, Gowrisree Sripada, Narayana Rao Mamidgi, Baswaraj Jalukuru, Charan Firmal, Priyanka Yechuri, Venkat Varanasi, Sowmya Peddireddi, Venkata Sudhakar Bhimarasetty, Devi Madhavi Kanisetti, Sidharth Joshi, Niranjan Mohapatra, Prasant Pamarthi, Kiran Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB |
title | Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB |
title_full | Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB |
title_fullStr | Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB |
title_full_unstemmed | Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB |
title_short | Development and clinical validation of Swaasa AI platform for screening and prioritization of pulmonary TB |
title_sort | development and clinical validation of swaasa ai platform for screening and prioritization of pulmonary tb |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034902/ https://www.ncbi.nlm.nih.gov/pubmed/36959347 http://dx.doi.org/10.1038/s41598-023-31772-9 |
work_keys_str_mv | AT yellapugayatridevi developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT rudrarajugowrisree developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT sripadanarayanarao developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT mamidgibaswaraj developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT jalukurucharan developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT firmalpriyanka developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT yechurivenkat developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT varanasisowmya developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT peddireddivenkatasudhakar developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT bhimarasettydevimadhavi developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT kanisettisidharth developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT joshiniranjan developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT mohapatraprasant developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb AT pamarthikiran developmentandclinicalvalidationofswaasaaiplatformforscreeningandprioritizationofpulmonarytb |